Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy

被引：0

作者：

Cristina Chiriaco

Chiara Donini

Marco Cortese

Stefano Ughetto

Chiara Modica

Ilaria Martinelli

Alessia Proment

Letizia Vitali

Lara Fontani

Monica Casucci

Paolo Maria Comoglio

Silvia Giordano

Dario Sangiolo

Valeria Leuci

Elisa Vigna

机构：

[1] Candiolo Cancer Institute,Department of Oncology

[2] FPO-IRCCS,Present address: Department of Surgical, Oncological and Stomatological Sciences (DICHIRONS)

[3] University of Turin,Innovative Immunotherapies Unit

[4] Present address: Bios-Therapy,undefined

[5] Physiological System for Health S.p.A,undefined

[6] University of Palermo,undefined

[7] IRCCS San Raffaele Scientific Institute,undefined

[8] IFOM-FIRC Institute of Molecular Oncology,undefined

来源：

Journal of Experimental & Clinical Cancer Research | / 41卷

关键词：

MET oncogene; Immunotherapy; CAR; Targeted therapy; Gastric cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
Chiriaco, Cristina
Donini, Chiara
Cortese, Marco
Ughetto, Stefano
Modica, Chiara
Martinelli, Ilaria
Proment, Alessia
Vitali, Letizia
Fontani, Lara
Casucci, Monica
Comoglio, Paolo Maria
Giordano, Silvia
Sangiolo, Dario
Leuci, Valeria
Vigna, Elisa
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
[2] RAS mutations override sensitivity to anti-met targeted therapy
Leiser, D.
Medova, M.
Mikami, K.
Blank, W.
Streit, B.
Aebersold, D.
Zimmer, Y.
STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 725 - 725
[3] Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
Su, Zhipeng
Han, Yunchun
Sun, Qichen
Wang, Xiaoxiao
Xu, Ting
Xie, Wei
Huang, Xing
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (01) : 100 - 111
[4] Active Cancer Immunotherapy by Anti-Met Antibody Gene Transfer
Vigna, Elisa
Pacchiana, Giovanni
Mazzone, Massimiliano
Chiriaco, Cristina
Fontani, Lara
Basilico, Cristina
Pennacchietti, Selma
Comoglio, Paolo M.
CANCER RESEARCH, 2008, 68 (22) : 9176 - 9183
[5] Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?
Lonez, Caroline
Breman, Eytan
CELLS, 2024, 13 (02)
[6] Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma
Okuda, Takeshi
Tasaki, Takayuki
Nakata, Susumu
Yamashita, Kimihiro
Yoshioka, Hiromasa
Izumoto, Shuichi
Kato, Amami
Fujita, Mitsugu
ANTICANCER RESEARCH, 2017, 37 (07) : 3871 - 3876
[7] Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer
Makoto Nishio
Atsushi Horiike
Hiroshi Nokihara
Hidehito Horinouchi
Shinji Nakamichi
Hiroshi Wakui
Fumiyoshi Ohyanagi
Keita Kudo
Noriko Yanagitani
Shunji Takahashi
Yasutoshi Kuboki
Noboru Yamamoto
Yasuhide Yamada
Masaichi Abe
Takashi Tahata
Tomohide Tamura
Investigational New Drugs, 2015, 33 : 632 - 640
[8] Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer
Nishio, Makoto
Horiike, Atsushi
Nokihara, Hiroshi
Horinouchi, Hidehito
Nakamichi, Shinji
Wakui, Hiroshi
Ohyanagi, Fumiyoshi
Kudo, Keita
Yanagitani, Noriko
Takahashi, Shunji
Kuboki, Yasutoshi
Yamamoto, Noboru
Yamada, Yasuhide
Abe, Masaichi
Tahata, Takashi
Tamura, Tomohide
INVESTIGATIONAL NEW DRUGS, 2015, 33 (03) : 632 - 640
[9] Radiation therapy enhances anti-tumor activity of a MET CAR T-based immunotherapy for glioblastoma
Hovhannisyan, L.
Aebersold, D. M.
Medova, M.
Ochsenbein, A. F.
Maher, J.
Zimmer, Y.
NEURO-ONCOLOGY, 2022, 24
[10] Mesothelin-targeted CAR-T cell therapy for solid tumors
Klampatsa, Astero
Dimou, Vivian
Albelda, Steven M.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 473 - 486

← 1 2 3 4 5 →